What question did this study set out to answer?

To assess the development and feasibility of CoughRetrain, a telehealth program for managing refractory chronic cough (RCC).

May 30, 2026Open Access

The CoughRetrain Program: Restoring Control Through a Non-pharmacological Intervention

Key Points

To assess the development and feasibility of CoughRetrain, a telehealth program for managing refractory chronic cough (RCC).
Developed following Medical Research Council guidance with stages including problem identification, evidence review, and testing.
Conducted a single-group feasibility pilot with twelve adults having RCC, focusing on adherence and adverse events.
Evaluated various self-efficacy and quality of life measures pre- and post-intervention.
Out of twelve enrolled, eleven participants completed the program with all core components successfully delivered.
Cough-specific self-efficacy improved by 0.3 ± 0.6, and cough-related quality of life increased by 3.6 ± 3.0 points (95% CI 1.5 to 5.6).
24-hour cough frequency decreased by 48% (95% CI -74% to +3%), indicating significant improvements.

Abstract

PURPOSE: Non-pharmacological cough interventions are recommended for refractory chronic cough (RCC), yet structured development processes and integration of behavioral theory are rarely described. We report on the development and feasibility of CoughRetrain, a theory-informed telehealth behavioral program that integrates behavior-change strategies to support voluntary control of coughing in RCC. METHODS: CoughRetrain was developed following Medical Research Council guidance through staged problem identification, evidence review, multidisciplinary refinement, remote adaptation, and formative testing in interstitial lung disease. The final five-session individual program integrates education, graded suppression practice, motivational interviewing, and goal setting. A single-group feasibility pilot in adults with RCC assessed adherence, fidelity, adverse events, general self-efficacy (New General Self-Efficacy Scale), cough-specific self-efficacy (Cough-Specific Self-Efficacy Scale), cough-related quality of life Leicester Cough Questionnaire (LCQ), cough severity visual analogue scale (CS-VAS), and 24-hour objective cough frequency. RESULTS: Twelve participants were enrolled, and eleven (median age 51 38-63 years; 55% female; median cough duration 6 3-20 years) completed the program. All core components were delivered. Two non-serious adverse events occurred (urticaria; headache). General self-efficacy remained stable (mean change 0.04 ± 0.19). Cough-specific self-efficacy increased by 0.3 ± 0.6. LCQ increased by 3.6 ± 3.0 points (95%CI 1.5 to 5.6). CS-VAS decreased by 18.8 ± 25.0 mm (95%CI -35.7 to -1.9), and 24-hour cough frequency decreased by 48% (95%CI -74% to +3%). CONCLUSIONS: CoughRetrain is a safe and feasible telehealth intervention for RCC developed through a transparent, patient-informed process. Preliminary findings align with behavioral cough literature. Larger controlled studies evaluating long-term efficacy are warranted.

Mark Helpful

Bookmark

Relay

View Full Paper